Novo Nordisk A/S

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 33,000 people in 75 countries, and markets its products in 190 countries. For more than a decade, Novo Nordisk has pursued a Triple Bottom Line business philosophy, ensuring it balances social and environmental concerns with financial performance.

Novo Nordisk has played a role in improving the lives of people with diabetes in China for nearly 50 years. Today, Novo Nordisk employs more than 3,200 people in China and has trained more than 400,000 Chinese healthcare professionals in diabetes treatment and prevention. In 1997, Novo Nordisk was the first international pharmaceutical company to establish a Research and Development centre in China. In 2012, Novo Nordisk will inaugurate a new state-of-the-art R&D facility with 150 staff, resulting in an additional investment of USD 100 million. Novo Nordisk is also expanding its Tianjin manufacturing facilities with an investment of USD 400 million. Novo Nordisk in China engages in a number of important research and management partnerships and raises public awareness through collaboration with stakeholders and its Changing Diabetes® initiative.

诺和诺德拥有89年历史，是一家始终致力于创新的公司，是糖尿病领域的领先者。诺和诺德同时也在血友病、生长激素治疗以及激素替代疗法等领域处于领先地位。诺和诺德总部位于丹麦首都哥本哈根。截至2010年底，在全球75个国家和地区拥有33000万名员工，产品行销近190个国家和地区。十余年间，诺和诺德秉承“三重底线”的商业理念，追求财务业绩和社会及环境发展的多重平衡。

过去近五十年中，诺和诺德在中国一直以提高糖尿病患者生活质量为己任。今天，诺和诺德在华员工总数超过3,200人，累计培训预防和治疗糖尿病的医疗专业人士400,000人以上。1997年，诺和诺德是第一家在中国建立研发中心的跨国制药企业。2012年，诺和诺德投资1亿美金全新扩建的，拥有150名研发人员的研发中心将开始使用。诺和诺德同时不断扩大天津生产基地，投资4亿美金的生产工厂计划在2013年开始生产。诺和诺德中国通过“改变糖尿病”活动参与一系列重要研究和合作项目并且提高了公众对糖尿病的意识。